Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 11 systematic review(s)/meta-analysis(es). ^[1-11]
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) Treatment Outcomes: In patients with Ph+ ALL, the three-agent regimen combining tyrosine kinase inhibitor (TKI), blinatumomab, and steroids achieved a pooled complete molecular response (CMR) rate of 81% (95% confidence interval (CI): 69%-89%), with a nearly 6-fold increased likelihood of complete molecular response (CMR) compared to TKI alone (odds ratio (OR): 5.98; 95% CI: 2.99-11.96) and a 5-fold increase in 1-year survival (OR: 5.1; 95% CI: 1.74-14.9).
• Pediatric relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL): In R/R B-ALL among pediatric patients, single-arm studies showed a complete remission (CR) rate of 0.56 (95% CI: 0.45-0.68) and an overall survival (OS) rate of 0.43 (95% CI: 0.32-0.54). In randomized controlled trials (RCTs), blinatumomab compared to chemotherapy improved OS (0.12; 95% CI: 0.05-0.19) and event-free survival (EFS) rates (2.16; 95% CI: 1.54-3.03).
• R/R B-ALL and NHL Responses: In relapsed/refractory B-ALL and non-Hodgkin lymphoma (NHL), the pooled CR rate for ALL was 0.45 (95% CI: 0.37-0.53), with higher CR observed in patients with bone marrow blasts below 50% (0.75) compared to those with blasts at or above 50% (0.33).
• Adult R/R BCP ALL: In adult R/R B-cell precursor (BCP) ALL, first salvage treatment resulted in a longer median OS (10.4 months) compared to second or later salvage (5.7 months; HR: 1.58; 95% CI: 1.26-1.97) and a higher remission rate (54% vs. 41%).
• Adverse Events in Pediatric R/R B-ALL: In single-arm studies, the adverse event (AE) rate was 0.65 (95% CI: 0.54-0.76), with Grade ≥3 AEs observed in 80% (95% CI: 72%-88%), including Grade ≥3 neurological toxicity at 7% (95% CI: 4%-11%) and cytokine release syndrome (CRS) at 3% (95% CI: 2%-5%).
• Comparison to Chemotherapy in Pediatric B-ALL: Blinatumomab was associated with a lower risk of serious AEs (RR: 0.56; 95% CI: 0.32-0.99), febrile neutropenia (RR: 0.13; 95% CI: 0.06-0.26), and infection (RR: 0.40; 95% CI: 0.29-0.56) compared to chemotherapy, though the risk of encephalopathy was higher (RR: 8.90; 95% CI: 1.08-73.29).
• Safety in R/R BCP ALL During Salvage Treatment: Higher frequencies of cytokine release syndrome, febrile neutropenia, and infection were observed in patients undergoing second or later salvage treatments compared to first salvage.
• Higher effectiveness was observed in Ph+ ALL patients treated with TKIs, blinatumomab, and steroids, particularly with ponatinib over dasatinib. In pediatric R/R B-ALL, CR rates were greater in patients with bone marrow blasts below 50%. Adult R/R BCP ALL showed improved outcomes with first salvage treatment compared to later salvage, and ALL patients had better response rates than NHL patients, with reduced tumor load further supporting clinical response in ALL.